Herman McDaniel, DO
Urogynecology and Reconstructive Pelvic Surgery · Apple Valley, CANPI 1063524130
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,184 of the $12,505 with a category attached, or 89.4%. 24 manufacturers reported payments, led by Caldera Medical, Inc at 38.6% of the total. Reporting peaked in 2024 at $2,882 and has fallen 64.7% since, to $1,016 in 2025.
Across 253 payments — averaging $49.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$5K
- Medtronic$3K
- Teleflex LLC$889
- Axonics, Inc.$792
- Boston Scientific$711
- Abbott$520
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$1151%
- Travel & lodging$1,1489%
- Food & beverage$11,18489%
- Education$580%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 44 | $4,830 |
| Medtronic(2 entities) | 105 | $2,723 |
| Teleflex LLC | 7 | $889 |
| Axonics, Inc. | 11 | $792 |
| Boston Scientific | 25 | $711 |
| Abbott | 11 | $520 |
| Mimedx Group, Inc. | 5 | $452 |
| Integra Lifesciences Corporation | 5 | $291 |
| Astellas Pharma US Inc | 12 | $259 |
| Hologic Sales And Service, LLC | 4 | $183 |
| Heron Therapeutics, Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Urocure LLC | 1 | $109 |
| Stimlabs LLC | 1 | $85 |
| Urovant Sciences Inc | 3 | $75 |
| Laborie Medical Technologies Corp. | 2 | $73 |
| AMAG Pharmaceuticals, Inc. | 3 | $58 |
| Pfizer | 3 | $47 |
| Coloplast | 3 | $39 |
| Antares Pharma, Inc. | 2 | $36 |
| 180 Medical, Inc. | 1 | $30 |
| Urogen Pharma, Inc. | 1 | $28 |
| AbbVie | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,505 in reported general payments places this provider in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 819 | $44,474 |
| ProgesteroneProgesterone, Micronized | 439 | $26,105 |
| MyrbetriqMirabegron | 26 | $17,089 |
| GemtesaVibegron | 24 | $16,833 |
| PremarinEstrogens, Conjugated | 28 | $12,978 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 23 | $1,692 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 85 | $1,584 |
| Estradiol (Twice Weekly)Estradiol | 19 | $1,539 |
| Ciprofloxacin Hcl | 203 | $968 |
| Medroxyprogesterone Acetate | 58 | $875 |
| Oxybutynin Chloride | 51 | $535 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $381 |
| Levothyroxine Sodium | 17 | $380 |
| Anastrozole | 27 | $265 |
| Fluconazole | 19 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $259 | $17,08926 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $16,83324 claims |
| PfizerPremarin | $47 | $12,97828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Apple Valley
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.